



ADULT Medication Monograph

VANCOMYCIN - ORAL

This document should be read in conjunction with this [DISCLAIMER](#)

[Formulary: Restricted](#)

 **HIGH RISK Medication**

| | |
|---|--|
| Class | Bactericidal glycopeptide |
| Presentation | Form: Strength Oral: 125mg, 250mg capsules |
| Storage | Store below 25°C. Protect from moisture |
| Dose | <u>Clostridioides difficile infection</u> Oral: 125mg every 6 hours for 10 days |
| Administration | <u>Oral:</u> <i>Oral capsules:</i> May be given at any time regarding food. <i><u>If oral capsules are not available, use vancomycin IV vial for oral administration:</u></i> Withdraw the contents of 1 vial (500mg) and dilute with 10mL of water. Concentration is 50mg/mL. Give patient 2.5mL (125mg) to drink. Flavouring syrups can be added before administration to improve palatability |
| Pregnancy | 1st Trimester: Considered safe to use 2nd Trimester: Considered safe to use 3rd Trimester: Considered safe to use |
| Breastfeeding | Safe to use |
| Monitoring | Ototoxicity – especially in longer courses and if used with other ototoxic drugs |
| Clinical Guidelines and Policies | WNHS Policies: Antimicrobial Stewardship (AMS) policy Micro Alerts and Multi-Resistant Organisms High Risk Medicines |

| | |
|-------------------|---|
| | <p>KEMH Clinical Guidelines:</p> <p>Adult Medication Monograph: Vancomycin (IV)</p> <p>Transmission based precautions</p> <p>KEMH Pharmaceutical & Medicines Management Guidelines:</p> <p>Medication Administration</p> |
| References | <p>The Royal Women's Hospital. Vancomycin. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2020 [cited 2020 Dec 30]. Available from: https://thewomenspbmg.org.au/</p> <p>Therapeutic Guidelines. Acute infectious diarrhoea: Clostridium difficile infection. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2019 [cited 2020 Dec 30]. Available from: https://tgldcdp.tg.org.au</p> <p>Trubiano JA, Cheng AC, Korman TM, et al. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J. 2016;46(4):479-493. doi:10.1111/imj.13027. Available from: https://onlinelibrary-wiley-com.kelibresources.health.wa.gov.au/doi/epdf/10.1111/imj.13027</p> |

| | | | |
|---|---|-------------------|----------|
| Keywords: | Vancomycin, C. difficile, Clostridium difficile, Clostridioides difficile, C. diff, CDAD | | |
| Publishing: | <input checked="" type="checkbox"/> Intranet <input checked="" type="checkbox"/> Internet | | |
| Document owner: | Chief Pharmacist | | |
| Author / Reviewer: | KEMH Pharmacy Department | | |
| Date first issued: | Dec 2020 | Version: | 1.0 |
| Last reviewed: | Information reviewed in combined vancomycin monograph Dec 2017, amended Jan 2019 and Aug 2019 and July 2020, Separate monograph for oral vancomycin created December 2020 | Next review date: | Dec 2023 |
| Endorsed by: | Medicines and Therapeutics Committee | Date: | Dec 2020 |
| Standards Applicable: | NSQHS Standards: 1  Governance, 3  Infection Control, 4  Medication Safety | | |
| <p>Printed or personally saved electronic copies of this document are considered uncontrolled.</p> <p>Access the current version from the WNHS website.</p> <p>For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au</p> | | | |

© Department of Health Western Australia 2020